Last reviewed · How we verify
PEGIntron plus ribavirin
PEGIntron (peginterferon alfa-2b) activates interferon signaling to suppress hepatitis C virus replication, while ribavirin inhibits viral RNA synthesis through multiple mechanisms.
PEGIntron (peginterferon alfa-2b) activates interferon signaling to suppress hepatitis C virus replication, while ribavirin inhibits viral RNA synthesis through multiple mechanisms. Used for Chronic hepatitis C virus infection (genotype-dependent).
At a glance
| Generic name | PEGIntron plus ribavirin |
|---|---|
| Sponsor | Hepatitis Resource Network |
| Drug class | Interferon alfa-2b (pegylated) + nucleoside analog |
| Target | Interferon-alpha receptor (IFNAR); viral RNA polymerase (ribavirin) |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
PEGIntron is a pegylated form of interferon alfa-2b that binds to interferon-alpha receptors on infected hepatocytes, triggering antiviral immune responses and inhibiting HCV replication. Ribavirin is a nucleoside analog that interferes with viral RNA synthesis and may enhance immune responses. The combination has synergistic antiviral activity against hepatitis C virus.
Approved indications
- Chronic hepatitis C virus infection (genotype-dependent)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hemolytic anemia
- Neutropenia
- Thrombocytopenia
- Depression / mood changes
- Headache
- Nausea
- Injection site reactions
Key clinical trials
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients (PHASE3)
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (PHASE3)
- Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |